PIK3CA and non-small cell lung carcinoma: In Sq-NSCLC, cfDNA enabled monitoring of copy number variation and identified a 71% overlap of PIK3CA gain in cfDNA and tumour tissue (phase II clinical trial, GO27912, NCT01493843 (93).